Regression of left ventricular hypertrophy in human hypertension with irbesartan
…, R Müller-Brunotte, F Nyström, KP Öhman… - Journal of …, 2001 - journals.lww.com
Objective Angiotensin II induces myocardial hypertrophy. We hypothesized that blockade of
angiotensin II subtype 1 (AT 1) receptors by the AT 1-receptor antagonist irbesartan would …
angiotensin II subtype 1 (AT 1) receptors by the AT 1-receptor antagonist irbesartan would …
Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients
…, T Kahan, K Malmqvist, KP Öhman… - Journal of …, 2001 - journals.lww.com
… Julia a ; Kahan, Thomas b ; Malmqvist, Karin b ; Öhman, K. Peter c ; Nyström, Fredrik c ; Hägg…
Potential conflicts of interest: Drs Lind and Öhman have become affiliated with AstraZenica …
Potential conflicts of interest: Drs Lind and Öhman have become affiliated with AstraZenica …
The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol …
…, L Lind, T Kahan, K Malmqvist, KP Öhman… - Journal of …, 2002 - journals.lww.com
Background The cytochrome P450 CYP2C9 enzyme (CYP2C9) metabolizes many clinically
important drugs, for example, phenytoin, warfarin and the angiotensin II type 1 (AT 1) …
important drugs, for example, phenytoin, warfarin and the angiotensin II type 1 (AT 1) …
Beta1‐adrenergic receptor gene polymorphisms and response to Beta1‐adrenergic receptor blockade in patients with essential hypertension
…, L Kurland, T Kahan, K Malmqvist, KP Öhman… - Clinical …, 2004 - Wiley Online Library
Background: Studies suggest that the Ser49Gly and Arg389Gly polymorphisms in the β 1 ‐adrenergic
receptor might be of functional importance for the cardiovascular system. Both …
receptor might be of functional importance for the cardiovascular system. Both …
Relationships between left ventricular mass and the renin–angiotensin system, catecholamines, insulin and leptin
K Malmqvist, KP Öhman, L Lind… - Journal of internal …, 2002 - Wiley Online Library
Malmqvist K, Öhman KP, Lind L, Nyström F, Kahan T (Karolinska Institutet Danderyd Hospital,
Stockholm; Faculty of Health Sciences, Linköping; University Hospital, Uppsala, Sweden). …
Stockholm; Faculty of Health Sciences, Linköping; University Hospital, Uppsala, Sweden). …
Pitfalls in Doppler evaluation of diastolic function: insights from 3-dimensional magnetic resonance imaging
…, L Wigström, AF Bolger, T Ebbers, KP Öhman… - Journal of the American …, 1999 - Elsevier
Ultrasound-Doppler assessment of diastolic function is subject to velocity errors caused by
angle sensitivity and a fixed location of the sample volume. We used 3-dimensional phase …
angle sensitivity and a fixed location of the sample volume. We used 3-dimensional phase …
Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake
KP Öhman, B Kågedal, R Larsson… - Journal of …, 1985 - journals.lww.com
Nine patients with essential hypertension treated with bendroflumethiazide were given
captopril 25 mg orally on three occasions to study the pharmacokinetics and blood pressure …
captopril 25 mg orally on three occasions to study the pharmacokinetics and blood pressure …
Pharmacokinetic‐Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes …
B Hamrén, KP Öhman, MK Svensson… - The Journal of …, 2012 - Wiley Online Library
The effects of tesaglitazar on renal function (assessed as urinary clearance of 125 I‐sodium
iothalamate or estimated by the modification of diet in renal disease formula) were studied in …
iothalamate or estimated by the modification of diet in renal disease formula) were studied in …
Tesaglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance
…, I Gause-Nilsson, S Halldórsdóttir, KP Öhman… - Atherosclerosis, 2008 - Elsevier
AIM: To determine the effects of the peroxisome proliferator-activated receptor (PPAR) α/γ
agonist tesaglitazar on serum levels of apolipoprotein (apo) AI, apoB, and apoCIII in non-…
agonist tesaglitazar on serum levels of apolipoprotein (apo) AI, apoB, and apoCIII in non-…
Serum leptin concentrations in a normal population and in GH deficiency: negative correlation with testosterone in men and effects of GH treatment
…, M Österlund, T Lindström, KP Öhman… - Clinical …, 1997 - Wiley Online Library
OBJECTIVE To study relationships between leptin and factors regulating body composition
as well as metabolic risk factors. Furthermore, to study the effects of GH on leptin. DESIGN …
as well as metabolic risk factors. Furthermore, to study the effects of GH on leptin. DESIGN …